<p><strong><span class="xn-location">SOUTH SAN FRANCISCO</span> </strong>&#8212; Freenome, a privately held biotech company, has landed a Series D funding of <span class="xn-money">$300 million</span>. This brings the company&#8217;s total financing to over <span class="xn-money">$800 million</span> since the company was founded in 2014.</p>
<p>This round was led by Perceptive Advisors and RA Capital Management, joined by existing investors including a16z Life Sciences Growth Fund, the American Cancer Society&#8217;s BrightEdge Ventures, Artis Ventures, Bain Capital Life Sciences, Catalio Capital Management, Cormorant Capital, DCVC, Farallon Capital Management, Fidelity Management and Research Company LLC, GV, Janus Henderson Investors, Kaiser Permanente, Novartis, Polaris Partners, Ridgeback Capital Management, Roche Venture Fund, Rock Springs Capital, Sands Capital, Section 32, Soleus Capital Management, with funds and accounts advised by T. Rowe Price Associates, Inc.</p>
<p>In addition, there were several new biotech institutional investors well-placed to support the company&#8217;s mission including ArrowMark Partners, Byers Capital, Eventide Asset Management LLC, HBM Healthcare Investments, Intermountain Ventures, Logos Capital, Pura Vida Investments, Suvretta Capital Management, and other undisclosed funds.</p>
<p>The funding will support the advancement of the company&#8217;s colorectal cancer (CRC) screening test and expansion of its multiomics platform to other cancers. Freenome&#8217;s platform uses a routine blood test to detect cancer in its earliest stages, when it is most treatable.</p>
<p>It is estimated that nearly 53,000 people will die from CRC this year and only 67% of average-risk individuals over the age of 50 are up to date on CRC screening. With recent guideline changes lowering the age from 50 to 45, even more people need to be screened. Freenome&#8217;s multiomics blood test can help address adherence challenges with existing approaches by providing a convenient and patient-friendly option. The test is being validated in PREEMPT CRC, Freenome&#8217;s large, prospective registrational study, currently in the final stages of enrollment.</p>
<p>The company is also extending its platform to develop tests for other cancers and recently presented promising <u>data</u> in the detection of pancreatic cancer.</p>
<p>&#8220;We appreciate the shared belief our investors have in what is possible when it comes to fighting cancer,&#8221; said <span class="xn-person">Mike Nolan</span>, chief executive officer of Freenome. &#8220;This funding gets us closer to bringing our early cancer detection tests to everyone, ultimately saving lives.&#8221;</p>
<p>&#8220;We&#8217;re excited about Freenome&#8217;s multiomics platform and its ability to detect not just CRC but also other cancers,&#8221; said Ellen Hukkelhoven, Ph.D., Perceptive Advisors. &#8220;We&#8217;re proud to help drive continued progress in bringing Freenome&#8217;s tests to the forefront of patient care.&#8221;</p>

SAN FRANCISCO -- Wispr, the voice-to-text AI that turns speech into clear, polished writing in every…
SAN FRANCISCO -- Numeric, an AI accounting automation platform, has raised a $51 million Series…
Apple has announced 45 finalists for this year’s App Store Awards, recognizing the best apps…
The University of California (UC) and the California Nurses Association (CNA) have reached a tentative…
SAN FRANCISCO -- House Rx, a health tech company focused on making specialty medications more accessible and…
Britain's King has given an award to the King of NVIDIA! NVIDIA founder and CEO…